Weight Loss Injections for Type 1 Diabetes: What You Need to Decide First

Why the licensing gap exists, and why it matters for your decision

The first thing worth understanding is why GLP-1 medicines do not currently carry a UK licence for type 1 diabetes. It is not simply a regulatory delay. The licensed weight-loss medicines in the UK (tirzepatide (Mounjaro) and semaglutide (Wegovy)) were studied in large trials almost exclusively in people with obesity who either had type 2 diabetes or no diabetes at all. The SURMOUNT-1 trial that established tirzepatide's weight-loss profile, for instance, excluded people with type 1 diabetes entirely.

That exclusion exists because the interaction between GLP-1 activity and insulin-dependent physiology raises specific concerns. In type 1 diabetes, the pancreas produces little or no insulin; GLP-1 medicines work partly through glucose-dependent insulin secretion, a pathway that behaves differently when insulin is being injected externally rather than produced naturally. Reducing appetite and slowing gastric emptying also changes when and how much carbohydrate enters the bloodstream, which has direct implications for insulin dosing and the risk of hypoglycaemia or, at the other end, DKA.

None of this makes weight loss injections categorically impossible for someone with type 1 diabetes. Small studies and case series have looked at GLP-1 use in this group, and some specialist clinicians do prescribe off-label where the clinical case is strong. But prescribing off-label means taking on risk that has not been fully quantified in large trials, and it requires a level of diabetes expertise (close glucose monitoring, insulin dose adjustment, ketone awareness) that goes well beyond a standard weight-management consultation. Your decision here is not really about which injection; it is about whether your diabetes team is involved and equipped to manage that process safely with you.

The specific risks that change the calculus for type 1 diabetes

Two risks are worth naming clearly, because they are the ones your diabetes team will weigh most carefully. The first is hypoglycaemia. GLP-1 medicines reduce appetite substantially; if you eat less than your insulin dose accounts for, blood sugar can drop. In type 2 diabetes managed with lifestyle or metformin alone, this is rarely a problem. In type 1 diabetes, where insulin is always in the picture, the margin is narrower and the consequences of getting it wrong are serious.

The second is diabetic ketoacidosis. There have been cases (including with GLP-2 and SGLT-2 medicines in type 1 diabetes) where reduced carbohydrate intake and unchanged or insufficient insulin created conditions for euglycaemic DKA: normal or near-normal blood glucose alongside dangerous ketone levels. The NHS tirzepatide patient information does not address this scenario specifically, because the medicine is not licensed in this context. That is exactly why specialist oversight is essential rather than optional.

On the practical side, anyone injecting a weekly GLP-1 medicine alongside daily insulin needs a clear protocol for what to do if nausea is severe enough to reduce food intake significantly on a dosing week. That protocol needs to come from your diabetes team. If you are planning an extended holiday, a hospital appointment or a shift in your routine that disrupts your injection schedule, those are conversations to have with your specialist in advance rather than questions for an online pharmacy to answer after the fact.

What is available through a licensed, regulated route, and where type 1 diabetes sits

For people with type 2 diabetes, the picture is clearer. Tirzepatide (Mounjaro) holds a UK licence for type 2 diabetes as well as for weight management, and semaglutide in its Ozempic form is licensed for type 2 diabetes. You can read more about how licensed weight loss injections relate to diabetes generally on this overview of weight loss injections used in diabetes. The situation for type 1 diabetes is different, and conflating the two does not serve you.

For weight management in adults with obesity or overweight and certain weight-related conditions, NICE has recommended tirzepatide (TA1026) and semaglutide (TA875) through specific criteria, but those recommendations do not extend to type 1 diabetes. If you want to understand whether diabetes injections are considered safe for weight loss in a broader sense, that page covers the licensed evidence in more detail.

If your diabetes team has reviewed your situation and is supportive of a trial of a licensed medicine off-label, a GPhC-registered prescriber at a regulated UK pharmacy can issue a prescription, but only after a consultation that takes your full diabetes history into account, including your current insulin regimen and your monitoring setup. A real clinician reviews every consultation at nume; there is no automated approval pathway, and a type 1 diabetes history would prompt careful individual assessment rather than a straightforward sign-off. Start your free consultation to put your situation to our prescribing team directly.

Who to talk to, and how to frame the conversation with your diabetes team

The clearest guidance is this: your diabetes specialist or consultant is the right starting point, not a weight-loss clinic. That is not a deflection. It reflects the fact that safe use in type 1 diabetes requires someone with access to your HbA1c trends, your hypoglycaemia history, your current insulin-to-carbohydrate ratios and your ketone monitoring habits, information a general weight-management prescriber simply does not hold.

When you have that conversation, it helps to be specific. Ask whether GLP-1 therapy has been considered for your situation, what monitoring would be needed if it were trialled, and whether your clinic has experience managing it in other patients with type 1 diabetes. Some diabetes centres in the UK have done exactly this, in a structured way, with close follow-up, and you can find out more about what that looks like by reading about diabetes weight loss injections and the oversight they require.

You can also review the newer weight-loss and diabetes injections approved in the UK to understand what has changed recently in this space. If after speaking to your team you are looking for a private prescribing route that takes your diabetes seriously, our clinical team includes GPhC-registered independent prescribers who give every consultation the individual attention it requires, including those asking about type 2 diabetes weight loss injections and how the evidence from that group applies to their own situation. The NHS obesity treatment page also outlines the broader clinical pathways available, which can be a useful reference before your appointment.